Lonza and Index Ventures, a venture capital investment firm, have entered an exclusive agreement for process development and cGMP production of all biologics for Index Ventures’ portfolio of companies. The companies may add projects during the five-year agreement, as Index makes future investments.
“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, chief operating officer of Lonza Pharma & Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.”
Kevin Johnson, partner at Index Ventures, said, “Lonza has manufactured the majority of the antibody products I’ve worked on in the last 20 years and proved to be an excellent partner. I’m pleased that we’re now able to extend that expertise to our asset-centric portfolio companies, enabling them to benefit as though they were much larger organizations.”